Clinical trials: Tislelizumab
Oral Squamous Cell Carcinoma
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
Given the feasibility of induction chemotherapy in oral cancer and the encouraging remission rates achieved, we explore the clinical application prospects of using tislelizumab in combination with traditional standard…
- Trial name
- B2023-153 (NCT06130007)
- Testing
- Three-Week Treatment Regimen with Trastuzumab in Combination with Docetaxel and Platinum Triple Therapy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Xuekui Liu
Hepatocellular Carcinoma
Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection
There are limited treatment options for HCC with high recurrence risk, and there is no consistent plan for adjuvant therapy after surgery. Hence an unmet clinical need.
- Trial name
- NCT05546619
- Testing
- HIPEC+tislelizumab + targeted therapy
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sulai Liu
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Cancer of Unknown Primary, Bone Cancer Metastatic
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Through scientific and rigorous design, implementation, follow-up and statistics, the sponsor aims to explore the clinical efficacy and safety of Tislelizumab combined with chemotherapy (platinum + paclitaxel) in the treatment of…
- Conditions
- Cancer of Unknown Primary, Bone Cancer Metastatic, Tislelizumab, Gene Mutation-Related Cancer
- Trial name
- NCT05241132
- Testing
- Tislelizumab plus chemotherapy
- Where
- China
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wei Xu
Non-small Cell Lung Cancer
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with standard first-line therapy to enhance the anti-tumor immune effect at the same time, thereby extending the…
- Trial name
- NCT06403111
- Testing
- Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Changzhou No.2 People's Hospital
NSCLC Stage IIIB, NSCLC Stage IIIC
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were…
- Trial name
- NCT06829641
- Testing
- Tislelizumab Combined with Chemotherapy,
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- West China Hospital
NSCLC Associated With Leptomeningeal Metastases
Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC
This is a prospective, single-arm, open clinical study, which was designed to evaluate the efficacy and safety of an immune checkpoint inhibitor combined with pemetrexed intrathecal injection in the treatment of patients with…
- Trial name
- NCT06132698
- Testing
- Tislelizumab or pembrolizumab, pemetrexed
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage, Unresectable
Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma
Whether the introduction of immunotherapy can transform unresectable esophageal cancer into resectable, or even achieve R0 surgical resection, has not been reported yet.
- Trial name
- NCT05449483
- Testing
- tislelizumab+ Paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer (SCLC)
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high.
- Trial name
- NCT05027100
- Testing
- Anlotinib Tislelizumab Irinotecan
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Haibo Zhang
Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
This is a single-arm，open-label study to evaluate the efficacy and safety of tislelizumab plus chemotherapy for conversion therapy of patients with locally nonresectable ESCC.
- Trial name
- NCT05469061
- Testing
- Tislelizumab, 5-FU, cis Platinum
- Where
- China
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
Gastric, Colorectal Adenocarcinoma
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
Objective of this study to evaluate 1-year disease-free survival in patients with dMMR/MSI-H or POLE/POLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after…
- Trial name
- NCT06118658
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- China Medical University, China
Non-Muscle Invasive Bladder Cancer, HER2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
This is a prospective, open, single-center clinical study of anti-HER2-ADC combined with PD-1 monoclonal antibody for bladder sparing treatment in non-muscular invasive bladder cancer (NMIBC) patients with HER2-expressing.
- Trial name
- NCT05957757
- Testing
- RC48, Tislelizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Bladder Cancer
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to…
- Trial name
- NCT05531123
- Testing
- Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Nasopharyngeal Cancinoma (NPC), SBRT
SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy
This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by…
- Conditions
- Nasopharyngeal Cancinoma (NPC), SBRT, Immunotherapy
- Trial name
- NCT06676722
- Testing
- SBRT combined with Nimotuzumab followed by Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Xiamen University
Stage III, Non-small Cell Lung Cancer
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer
This is a prospective, one-arm, phase II study aimed at evaluating tislelizumab combined with platinum-containing dual-drug chemotherapy as a neoadjuvant treatment, supplemented with tislelizumab after surgery in patients with…
- Trial name
- NCT04865705
- Testing
- tislelizumab
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- West China Hospital